Guidance is provided in a European setting on the assessment and treatment of
postmenopausal women with or at risk from osteoporosis. Introduction The European …

Antiresorptive agents help to restore skeletal balance by reducing bone turnover, primarily at
the tissue level. Another therapeutic approach is to enhance bone formation with the use of …

Objective The development of these guidelines is sponsored by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology …

Background Osteoporosis medications increase bone-mineral density (BMD) and lower but
do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has …

Context: Current osteoporosis medications increase bone mineral density (BMD) modestly
and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering …

Postmenopausal osteoporosis is the most common bone disease, associated with low bone
mineral density (BMD) and pathological fractures which lead to significant morbidity. It is …

Maintenance of bone integrity is mediated by the balanced actions of osteoblasts and
osteoclasts. Because macroautophagy/autophagy regulates osteoblast mineralization …

Postmenopausal women with severe osteoporosis may require treatment with the bone
anabolic drug teriparatide. While changes in bone mineral density (BMD) are one measure …

The pharmacological management of disease should involve consideration of the balance
between the beneficial effects of treatment on outcome and the probability of adverse effects …

Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …